| Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis 2026 · fish-oil group · Adults receiving maintenance hemodialysis | 800 mg | 4 g | 1278 days | 610 |
| n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes 2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction | 149 mg | 400 mg | 1217 days | 262 |
| CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study 2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye | 840 mg | 270 mg | 3 years | 127 |
| Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT) 2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA) | 2.1 g | 3 g | 240 days | 125 |
| Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation 2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding | 1.1 g | 1.6 g | — | 54 |
| Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy 2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies | 1.1 g | 1.6 g | — | 52 |
| Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo 2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk | 1.05 g | 2.2 g | 1 year | 23 |
| The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial 2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported | 1 g | 1.2 g | 52 weeks | 19 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 350 mg | 650 mg | 5 years | — |
| Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder 2019 · EPA + DHA group · Adults with major depressive disorder | 700 mg | 1.5 g | 12 weeks | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + placebo · Women in early pregnancy | 1.9 g | 220 mg | — | — |
| The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial 2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week | 450 mg | 90 mg | — | 43 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 350 mg | 650 mg | 5 years | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + probiotics · Women in early pregnancy | 1.9 g | 220 mg | — | — |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 400 mg | 113 mg | 3 years | 381 |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 400 mg | 113 mg | 3 years | 374 |
| The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial 2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated | 800 mg | 100 mg | — | 351 |
| Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study 2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease | 1 g | 2 g | 1 year | 349 |
| Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye 2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye | 240 mg | 360 mg | 90 days | 220 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 900 mg | 270 mg | 26 weeks | 113 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 360 mg | 900 mg | 26 weeks | 112 |
| Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial 2009 · fish oil · Thai schoolchildren aged 9 to 12 years | 1 g | 200 mg | 26 weeks | 94 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 1.7 g | 600 mg | 1 year | 89 |
| Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study 2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation | 1.7 g | 600 mg | 26 weeks | 88 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 200 mg | 300 mg | 26 weeks | 87 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 1.7 g | 600 mg | 26 weeks | 85 |
| Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial 2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes | 560 mg | 1.68 g | 12 weeks | 66 |
| Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial 2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months | 1 g | 2 g | 90 days | 56 |
| Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men 2017 · LCPUFA group · Japanese men aged 55–64 years | 300 mg | 100 mg | 4 weeks | 51 |
| The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial 2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment | 480 mg | 720 mg | 26 weeks | 44 |
| Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial 2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy | 210 mg | 420 mg | 1 year | 40 |
| Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial 2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years | 2.2 g | 1.1 g | — | 33 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 71.9 mg/kg | 242 mg/kg | 1 year | 33 |
| The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18 | 1.1 g | 3.2 g | 12 weeks | 30 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 900 mg | 270 mg | 26 weeks | 29 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 600 mg | 900 mg | 90 days | 27 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 360 mg | 900 mg | 26 weeks | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 780 mg | 2.13 g | 12 weeks | 27 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 800 mg | 1.6 g | 24 weeks | 26 |
| Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial 2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis | 400 mg | 740 mg | 16 weeks | 25 |
| Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial 2007 · n-3 EFA group · Patients presenting after recurrent self-harm | 900 mg | 1.2 g | 12 weeks | 22 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 800 mg | 1.6 g | 24 weeks | 21 |
| Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis 2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder | 780 mg | 1.47 g | 12 weeks | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea | 720 mg | 1.08 g | 60 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea | 720 mg | 1.08 g | 60 days | 21 |
| Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure 2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure | 1.2 g | 1.8 g | 6 weeks | 20 |
| Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder 2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17 | 200 mg | 1 g | 8 weeks | 20 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 18 mg/kg | 27 mg/kg | 24 weeks | 20 |
| Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial 2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male | 1 g | 2 g | 12 weeks | 20 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment | 1.55 g | 400 mg | 26 weeks | 18 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 780 mg | 940 mg | 30 days | 18 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment | 160 mg | 1.67 g | 26 weeks | 17 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 36 mg/kg | 54 mg/kg | 24 weeks | 17 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 800 mg | 1.6 g | 24 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 120 mg | 300 mg | 90 days | 15 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 500 mg | 250 mg | 90 days | 13 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 1 g | 12 weeks | 13 |
| Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise 2008 · DHA + EPA · Healthy adult men and women; ages not reported | 2 g | 3 g | 6 weeks | 12 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 260 mg | 600 mg | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 1 g | 2 g | 12 weeks | 12 |
| 4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions 2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated | 260 mg | 3 g | 33 days | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 2 g | 12 weeks | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 4 g | 12 weeks | 11 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 260 mg | 600 mg | 62 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 1.58 g | 2.28 g | 10 weeks | 10 |
| Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study 2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported | 500 mg | 1 g | 90 days | 8 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 260 mg | 600 mg | 62 days | 8 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 500 mg | 250 mg | 90 days | 6 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 2.2 g | — | 3 weeks | 5 |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 2 · Patients with active rheumatoid arthritis | 2 g | 3.8 g | 16 weeks | — |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 3 · Patients with active rheumatoid arthritis | 2 g | 3.8 g | 16 weeks | — |
| Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study 2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior | 700 mg | 1.5 g | 6 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 1.7 g | 600 mg | 26 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 1.7 g | 600 mg | 26 weeks | — |
| Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers 2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs | 500 mg | 2.5 g | 90 days | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · fish-oil group · healthy pregnant women | 500 mg | 150 mg | — | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · combined fish-oil and 5-MTHF group · healthy pregnant women | 500 mg | 150 mg | — | — |
| Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study 2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy | 340 mg | 510 mg | 66 days | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 400 mg | 300 mg | 8 weeks | — |
| The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial 2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported | 360 mg | 540 mg | 120 days | — |
| Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study 2014 · omega-3 fatty acid supplementation · Regular cigarette smokers | 2.04 g | 2.71 g | 30 days | — |
| Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients 2014 · omega-3 fatty acids group · Adults with depressive symptoms (BDI score ≥16) receiving maintenance hemodialysis for at least 3 months | 720 mg | — | 120 days | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · ADHD Active · Boys aged 8–14 with ADHD | 650 mg | 650 mg | 16 weeks | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI | 650 mg | 650 mg | 16 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder | 260 mg | 1.06 g | 8 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder | 900 mg | 180 mg | 8 weeks | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 350 mg | 650 mg | 5 years | — |
| Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements 2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported | 1.47 g | 147 mg | 12 weeks | — |
| ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers 2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD | 225 mg | 338 mg | 90 days | — |
| Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players 2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated | 1.1 g | 3.09 g | 5 weeks | — |
| Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists 2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week | 975 mg | 1.22 g | 30 days | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.65 g | 1.95 g | 16 weeks | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.65 g | 1.95 g | 16 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.14 g | 1.71 g | 1 year | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 400 mg | 1 g | 18 weeks | 134 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 100 mg | 12 weeks | 96 |
| Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial 2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode | 600 mg | 1.9 g | 12 weeks | 46 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 480 mg | 1.42 g | 12 weeks | 40 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 100 mg | 24 weeks | 40 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 400 mg | 600 mg | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 2.6 g | 26 weeks | 24 |
| The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment 2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment | 4.14 g | 810 mg | 26 weeks | 23 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 137 mg | 590 mg | 30 days | 22 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 417 mg | 159 mg | 30 days | 22 |
| Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial 2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled | 188 mg | 570 mg | 12 weeks | 21 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 2.6 g | 90 days | 20 |
| Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported. | 4.14 g | 810 mg | 913 days | 20 |
| Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study 2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus | 500 mg | 602 mg | 90 days | 19 |
| 21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo 2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified | 1.02 g | 10 g | 3 weeks | 18 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 504 mg | 120 mg | 6 weeks | 16 |
| A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study 2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill | 1 g | 160 mg | 24 weeks | 15 |
| Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male 2025 · EPA/MCT group · Healthy young men | 260 mg | 600 mg | 8 weeks | 10 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 140 mg | 216 mg | 6 weeks | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 350 mg | 650 mg | 5 years | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 225 mg | 706 mg | 90 days | — |
| EPA and DHA as markers of nutraceutical treatment response in major depressive disorder 2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported | 656 mg | 1 g | 8 weeks | — |
| Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass 2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall | 1.5 g | 3 g | 26 weeks | — |
| Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial 2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder | 225 mg | 1.04 g | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 1.95 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 1.95 g | 16 weeks | — |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 1.2 g | 1.6 g | 12 weeks | 12 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 3.7 g | 1.7 g | 4 weeks | 21 |
| Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective? 2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women | 240 mg | 360 mg | 180 days | 470 |
| Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN) 2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD) | 1.14 g | 1.38 g | 24 weeks | 87 |
| Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial 2014 · 6:1-OM3 · Adult men and women with one or more cardiovascular disease risk factors, blood Omega-Score below 6.1%, and triglycerides 1.02–5.65 mmol/L | 440 mg | — | 8 weeks | 56 |
| Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus 2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks | 616 mg | 120 mg | — | 42 |
| Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry 2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated | 1 g | 2 g | 6 weeks | 41 |
| Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index 2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5% | 300 mg | 200 mg | 8 weeks | 40 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 1.77 g | 656 mg | 14 weeks | 37 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 506 mg | 429 mg | 1 year | 35 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 506 mg | 429 mg | 1 year | 30 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 13.6 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 13.8 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 14.7 mg | 1 day | 27 |
| Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study) 2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6% | 300 mg | 400 mg | 8 weeks | 20 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Calanus Oil condition · Healthy adults; age and sex not specified | 156 mg | 4 g | 1 day | 18 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · Lys-FFA · Eight female volunteers | 302 mg | 500 mg | 1 day | 8 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · EE · Eight female volunteers | 378 mg | 504 mg | 1 day | 8 |
| Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids 2006 · fish oil · 20 study participants; age, sex, and health condition not specified | 864 mg | 1.3 g | 8 weeks | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO · Pregnant women from gestation week 22 until delivery | 500 mg | 150 mg | — | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery | 500 mg | 150 mg | — | — |
| Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? 2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported | 700 mg | 1 g | 12 weeks | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Butter meal · Healthy adult men and women | 1.5 g | 300 mg | 1 day | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Sunflower seed oil meal · Healthy adult men and women | 1.5 g | 300 mg | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study | 370 mg | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · re-esterified TAG · Healthy men in the postprandial crossover study | 370 mg | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study | 370 mg | 1.1 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study | 370 mg | 1.1 g | 1 day | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 300 mg | 500 mg | 3 weeks | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 300 mg | 500 mg | 3 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 200 mg | 1.67 g | 12 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 200 mg | 1.67 g | 12 weeks | — |
| Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy 2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included | 800 mg | 1.2 g | 8 weeks | — |
| Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth? 2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified | 800 mg | 100 mg | — | — |
| Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels 2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline | 297 mg | 137 mg | 1 year | — |
| Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans 2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis | 800 mg | 1.1 g | 12 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · ethyl ester (EE) · healthy normolipaemic men | 1.2 g | 2.2 g | 7 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · triglyceride (TG) · healthy normolipaemic men | 1.4 g | 2.2 g | 7 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish diet group · Healthy men aged 19–32 years | 670 mg | 380 mg | 14 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish oil group · Healthy men aged 19–32 years | 950 mg | 1.33 g | 14 weeks | — |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.5 g | 1.86 g | 1 year | 147 |
| Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial 2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men | 1.5 g | 3.36 g | 913 days | 143 |
| Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial 2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml | 2.88 g | 4.48 g | 12 weeks | 126 |
| Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study 2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women | 1.7 g | 600 mg | 1 year | 89 |
| Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial 2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery | 1 g | 2 g | 7 days | 74 |
| Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes 2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity | 560 mg | 1.68 g | 12 weeks | 54 |
| Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial 2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis | 380 mg | 1 g | 1 year | 50 |
| Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study 2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted | 750 mg | 930 mg | 1 year | 48 |
| Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids 2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups | 380 mg | 460 mg | 8 weeks | 45 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 300 mg | 70 mg | 4 weeks | 40 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 600 mg | 140 mg | 4 weeks | 40 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 1.8 g | 4.4 g | 30 days | 40 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 274 mg | 1.06 g | 14 weeks | 37 |
| Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes 2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease | 1 g | 1 g | 90 days | 36 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 900 mg | 180 mg | 14 weeks | 36 |
| Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia 1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet | 4 g | 4 g | 12 weeks | 28 |
| Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers 2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years | 375 mg | 465 mg | 7 weeks | 28 |
| Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial 2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder | 200 mg | 2.4 g | 12 weeks | 28 |
| Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO) 2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications | 720 mg | 1.8 g | 8 weeks | 26 |
| Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study 2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified | 240 mg | 1.2 g | 6 weeks | 25 |
| Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers 2014 · Lovaza 4/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years | 1.5 g | — | 7 weeks | 25 |
| Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives 2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day | 400 mg | 1 g | 120 days | 24 |
| Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel | 480 mg | 720 mg | 8 weeks | 24 |
| Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial 2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation | 320 mg | 72 mg | — | 24 |
| Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism 2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease | 1.52 g | 1.84 g | 8 weeks | 24 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 1.45 g | 2.15 g | 6 weeks | 21 |
| Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults 2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults | 1 g | 1.5 g | 8 weeks | 21 |
| N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial 2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin | 1 g | 3 g | 8 weeks | 20 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia | 1.5 g | 1.86 g | 90 days | 19 |
| The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man 1997 · highly purified DHA · healthy men | 3.6 g | 3.6 g | 7 weeks | 19 |
| Dietary supplementation with fish oil in ulcerative colitis 1992 · fish oil · Adults with active ulcerative colitis | 2.16 g | 3.24 g | 120 days | 18 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 900 mg | 700 mg | 7 weeks | 17 |
| Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans 2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated | 600 mg | 1.5 g | 26 weeks | 16 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period | 750 mg | 930 mg | 90 days | 16 |
| Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes 2000 · Fish oil · Postmenopausal women | 1.4 g | 2 g | — | 15 |
| Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate 2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified | 1.4 g | 2 g | — | 15 |
| Omega-3 fatty acids effect on wound healing 2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years | 1.1 g | 1.6 g | 5 weeks | 15 |
| Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study 2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported | 19.2 mg | 6.25 mg | 26 weeks | 15 |
| Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial 2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years | 2.1 g | 240 mg | 10 weeks | 15 |
| An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia 2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported | 1.48 g | 1.88 g | 8 weeks | 14 |
| Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study 2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders | 2.21 g | 2.22 g | 6 weeks | 14 |
| Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects 1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects | 550 mg | 1.05 g | 6 weeks | 13 |
| Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial 2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease | 1.51 mg | 306 mg | 26 weeks | 13 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · EPA group · Adults older than 65 years with mild cognitive impairment | 160 mg | 1.67 g | 26 weeks | 12 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · DHA group · Adults older than 65 years with mild cognitive impairment | 1.55 g | 400 mg | 26 weeks | 12 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · High DHA-FO concentrate · Obese men and women with BMI >30 | 2 g | 400 mg | 12 weeks | 12 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 90 days | 11 |
| The influence of low intake of n-3 fatty acids on platelets in elderly people 1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated | 150 mg | 600 mg | 6 weeks | 10 |
| Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds 2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes | 1.2 g | 1.6 g | 4 weeks | 9 |
| [Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia] 1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported | 1.2 g | 1.8 g | 12 weeks | 8 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years | 1.52 g | 1.84 g | 8 weeks | 3 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 700 mg | 1.1 g | 150 days | 2 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 350 mg | 550 mg | 150 days | 1 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 1 g | 1.4 g | 12 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 1.1 g | 2.1 g | 12 weeks | — |
| Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins 2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation | 500 mg | 150 mg | — | — |
| Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery 1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L | 1.89 g | 3.15 g | 26 weeks | — |
| Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults 2010 · experimental group · healthy young adults | 1.2 g | 1.6 g | 4 weeks | — |
| Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation 2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant | 1.1 g | 1.6 g | — | — |
| Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients 2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years | 828 mg | 1.89 g | 8 weeks | — |
| Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified | 1.35 g | 3 g | 26 weeks | — |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 100 mg | 30 mg | 1 year | — |
| Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder 2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy | 195 mg | 635 mg | 8 weeks | — |
| Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study 2015 · n-3 FA treatment · Patients with Alzheimer's disease | 1.7 g | 600 mg | 26 weeks | — |
| The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions 2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated | 253 mg | 214 mg | 1 year | — |
| The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression 2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified | 800 mg | 4 g | 12 weeks | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported | 510 mg | 945 mg | 90 days | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported | 500 mg | 1 g | 90 days | — |
| Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial 2017 · omega-3 fatty acid group · Infants from birth to 6 months of age | 280 mg | — | 26 weeks | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 800 mg | 1.1 g | 12 weeks | — |
| The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial 2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes | 1.5 g | 1.86 g | 913 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 350 mg | 650 mg | 5 years | — |
| Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial 2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia | 280 mg | 700 mg | 90 days | 105 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 83.4 mg | 167 mg | 4 weeks | 24 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 300 mg | 4 weeks | 16 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 1.2 g | 3.6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 200 mg | 1.05 g | — | 10 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 120 mg | 180 mg | 4 weeks | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 350 mg | 650 mg | 5 years | — |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 400 mg | 1 g | 12 weeks | 25 |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 400 mg | 1 g | 12 weeks | 25 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 225 mg | 3 years | 399 |